This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
Cancer Cell International Open Access 24 August 2021
-
Targeting EphA2 in cancer
Journal of Hematology & Oncology Open Access 18 August 2020
-
Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia
Bone Marrow Transplantation Open Access 14 August 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. First approval in sight for Novartis' CAR-T therapy after panel vote. Nat Biotechnol 35, 691–693 (2017). https://doi.org/10.1038/nbt0817-691
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0817-691
This article is cited by
-
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
Cancer Cell International (2021)
-
Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia
Bone Marrow Transplantation (2021)
-
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Nature Biomedical Engineering (2021)
-
Targeting EphA2 in cancer
Journal of Hematology & Oncology (2020)
-
Engineering adeno-associated virus vectors for gene therapy
Nature Reviews Genetics (2020)